Lunesta eszopiclone: Phase IV data

In a 10-week, double-blind, placebo-controlled Phase IV trial in 595 patients, Lunesta significantly improved sleep onset, TST, WASO and

Read the full 195 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE